Biocon surges as its Bosaya, Vevzuo get NoC from Health Canada
Denosumab products play a key role in bone health by increasing bone mass and treating osteoporosis, as well as bone complications associated with cancer
Biocon is currently trading at Rs. 364.05, up by 5.55 points or 1.55% from its previous closing of Rs. 358.50 on the BSE.
The scrip opened at Rs. 360.45 and has touched a high and low of Rs. 364.60 and Rs. 359.00 respectively. So far 24592 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 424.95 on 18-Nov-2025 and a 52 week low of Rs. 308.80 on 25-Apr-2025.
Last one week high and low of the scrip stood at Rs. 364.60 and Rs. 346.95 respectively. The current market cap of the company is Rs. 59001.04 crore.
The promoters holding in the company stood at 54.45%, while Institutions and Non-Institutions held 29.10% and 16.45% respectively.
Biocon’s Bosaya (denosumab), a biosimilar to Prolia, and Vevzuo (denosumab), a biosimilar to Xgeva, have received Notice of Compliance (NOC) from Health Canada. Both biosimilars were approved in the most common presentations: BOSAYA, as a 60 mg/mL injection for subcutaneous use in a prefilled syringe; and VEVZUO, as a 120 mg/1.7 mL (70 mg/mL) injection for subcutaneous use in a single-dose vial.
Denosumab products play a key role in bone health by increasing bone mass and treating osteoporosis, as well as bone complications associated with cancer.
The approval is based on a comprehensive package of analytical, nonclinical, and clinical data, demonstrating that BOSAYA and VEVZUO are highly similar to PROLIA and XGEVA, respectively, with no clinically meaningful differences in quality, safety, or efficacy.
Biocon is India’s largest and Asia’s leading Biotechnology Company with a strategic focus on biopharmaceuticals and research services. It is a fully integrated, innovation driven biopharma enterprise offering affordable solutions for chronic diseases to patient's worldwide.
